Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus CHOP versus CHOP in previously untreated peripheral T-cell lymphoma
CTR20243546Phase 2Active
- Sponsor
- Yingli Pharma
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peripheral T-cell lymphoma (PTCL) comparing Linperlisib + CHOP with Placebo + CHOP (2 arms). Primary endpoint: Overall response rate. Started Sep 2024; status: active.
02
Drugs
linperlisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20243546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243546.